Clinical Study

Homocysteine May Involve in the Pathogenesis of Behcet’s Disease by Inducing Inflammation

Selda Pelin Kartal Durmazlar,1 Ahmet Akgul,2 and Fatma Eskioglu1

1 Department of Dermatology, Diskapi Yildirim Beyazit Education and Research Hospital, Ministry of Health Ankara, 06110 Ankara, Turkey
2 Department of Cardiovascular Surgery, Turkiye Yuksek Ihtisas Education and Research Hospital, Ministry of Health Ankara, 06100 Ankara, Turkey

Correspondence should be addressed to Selda Pelin Kartal Durmazlar, pelin@dr.com

Received 1 August 2008; Revised 2 November 2008; Accepted 17 November 2008

Recommended by Dennis Daniel Taub

Objective. Our aim was to evaluate the significance of homocysteine (Hcy) in Behcet’s disease (BD) and the association of elevated Hcy levels associated with the indices of inflammation in BD.

Methods. Untreated 70 patients with BD and 33 healthy individuals were included into the study. Hcy, tumor necrosis alpha (TNF-α), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated with respect to activity and specific individual clinical manifestations of the disease.

Results. Hcy levels were found significantly elevated in active BD when compared to inactive BD and healthy controls. Hcy levels were found to have high correlation with the number of active clinical manifestations increased. A significant positive correlation was found between serum Hcy and TNF-α levels, CRP, and ESR. Hcy was found to be the best predictor of TNF-α among other parameters.

Conclusion. Hcy may involve in the pathogenesis of BD by inducing inflammation.

Copyright © 2008 Selda Pelin Kartal Durmazlar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

In 1969, McCully first proposed homocysteine (Hcy) to be a cause of cardiovascular disease due to the observation that patients with homocystinuria, a metabolic disease which results in high Hcy levels, also displayed atherosclerotic plaques at autopsies [1]. High levels of Hcy were associated with endothelial damage and oxidative stress [2, 3]. Currently, there is a classification commonly used for the degree of hyperhomocysteinemia as follows: normal (5–14 μmol/L), mild (15–30 μmol/L), moderate (31–100 μmol/L), and severe (>100 μmol/L) [4]. As many epidemiologic studies supported, mild hyperhomocysteinemia was found risk factor for both venous and arterial thrombosis [5–8]. Hcy is an intermediary sulphhydryl-containing amino acid formed during the conversion of methionine to cysteine. Its sulphhydryl group can cause direct endothelial cytotoxicity, inhibition of glutathione peroxidase and nitric oxide, interference with clotting factor, and oxidation of LDL [9]. Additionally, high levels of Hcy cause lipid peroxidation, impaired vaso motor regulation, prothrombic surface, and, therefore, atherothrombogenesis [10].

Behcet’s disease (BD), initially described by Behcet in 1937 [11], is a chronic relapsing vasculitis, involving both arteries and veins of various sizes. Thrombotic complications have been reported in approximately 10–40% of BD patients [12]. Endothelial dysfunction due to inflammation is considered to be an important factor of thrombosis in BD. Homocysteine is reported to enhance endothelial leukocyte interaction [13]. Some studies have shown that hyperhomocysteinemia might be assumed to be an independent and correctable risk factor for thrombosis in BD [14–19]. Moreover, the association between Hcy levels and endothelial dysfunction has been shown in patients with BD [20]. However, endothelial injury itself cannot clearly account the hypercoagulable status of BD because other vasculitis syndromes do not increase the risk of thrombosis [21]. Additionally, existence of several contradictory results with respect to serum Hcy levels leads the role of homocysteine in BD unclear [22]. As vitamin B6, vitamin B12, and folic
acid can decrease homocysteine levels [23], treatment with these vitamins can be considered to reduce the risk of venous and arterial thrombosis. Therefore, it is important to find a clear picture of the role of Hcy, which is thought to induce proinflammatory cytokines [24] during the course of BD.

The present study was conducted to evaluate serum Hcy as a serological marker for the assessment of the activity of BD with respect to specific individual clinical manifestations. Serum levels of Hcy were compared with the values of C-reactive protein (CRP), an acute phase reactant, the erythrocyte sedimentation rate (ESR), and tumor necrosis alpha (TNF-α) which is an important proinflammatory cytokine. The results were controlled with the healthy individuals.

In patients with BD, the question of whether hyperhomocysteinemia depends on the inflammation has not been answered yet. Therefore, our aim was to evaluate whether elevated Hcy levels, an independent risk factor for both venous and arterial thrombosis, associated with proinflammatory process mediated by cytokines in patients with BD.

2. MATERIAL AND METHODS

2.1. Subjects

70 patients (40 males, 30 females; mean age of 33 ± 7.79) fulfilling the international study group criteria [25] for the diagnosis of BD and 33 healthy control subjects (17 males, 16 females; mean age of 30 ± 6.68) were included in this study. Patients with BD were selected from patients who were being followed up by the departments of dermatology and cardiovascular surgery, Behcet’s Disease Unit or referred from other departments. Subjects were newly diagnosed or patients who were not taking any medicine regarding BD. Subjects were matched healthy hospital staff. Complete blood count, serum glucose, urea, creatinine, total cholesterol, triglyceride, uric acid, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, vitamin B12, and folic acid levels were evaluated in all of the subjects before being included into the study. Patients who had other type of illness such as autoimmune disease that could affect the cytokine levels or patients taking any medication affecting the immune system or patients with folic acid or vitamin B12 deficiencies, diabetes mellitus, hyperlipidemia, chronic hepatitis, renal failure, severe psoriasis, pernicious anemia, and chronic alcoholism which might affect Hcy levels were excluded from the study. Patients taking vitamin supplements in the previous 6 months were also excluded from the study. The study was approved by the local ethics institute. Informed consent was obtained from all subjects. Pathergy test was performed and the number of active manifestations recorded for each patient.

2.2. Determination of disease activity

Since accepted specific clinical activity scoring system and laboratory screening profile for BD has not been performed so far, the activity of patients was considered to have an active disease in case of the existence of two or more symptoms with worsening of clinical symptoms and lack of wellbeing at the time of the study. Behçet’s disease activity index (BDAI) was also performed on our patients according to the method presented by Bhakta et al. [26] and described elaborately by Lawton et al. [27]. An overall disease activity scores derived from adding the scores according to the evaluation of the duration of each clinical features (from 0 to 4) and patients and clinicians impressions of the disease activity. As it was agreed that inclusion of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) measurements would not add significantly to overall measurement of disease activity [27] and were not included as criteria in BDAI [26, 27], ESR and CRP were not used in the determination of the activation of the disease. The patients who had no symptoms regarding BD in four weeks period or less than two symptoms with a healing process and an overall wellbeing status were grouped in inactive BD.

2.3. Vascular examination

All patients and healthy volunteers were examined carefully for vascular involvement. Either venous or arterial system involvement was defined as present when confirmed by Doppler ultrasonography, radioisotope venography, magnetic resonance angiography, conventional angiography, or computerized tomography.

2.4. Serum homocysteine analysis

Serum homocysteine levels in the study groups were determined by fluorescence polarization immunoassay (FPIA) technique (Axis Biochemicals, ASA, Oslo, Norway). FPIA was run on an IMx analyzer (Abbott, Ill, USA). The 95% confidence interval of plasma Hcy level suggested by the manufacturer for healthy individuals is 4.45–12.42 μmol/L and serum Hcy level is expected to be up to 10% higher than ethylenediamine tetraacetate (EDTA) plasma. Five cc blood samples were drawn using a 25 gauge needle from a peripheral vein, avoiding haemolysis in the morning hours after an overnight fasting and 30 minutes of supine rest and collected into 10 mL empty evacuated tubes without EDTA, heparin, or clot activators. Samples were centrifuged at 1000 × g for 10 minutes. The serum was separated in aliquots and immediately frozen and stored at −80°C within 60 minutes until use.

2.5. Detection of tumor necrosis alpha by enzyme-linked immunosorbant assay

The TNF-α level was measured with an enzyme-linked immunosorbant assay (ELISA) kit (Bender Medsystems, Vienna, Austria, Lot # 223/208-D1) with a detectable level set at 14 pg/mL. Five cc serum was separated by centrifugation at 1000 × g for 10 minutes and stored at −70°C until use.

2.6. C-reactive protein, erythrocyte sedimentation rate analyses

CRP was measured by a highly sensitive turbidimetric method using conventional biochemical automatic analyzer.
The upper limit of the normal range was 5 mg/L. The ESR was determined by the classic Westergren method.

2.7. Statistical analysis

Results were analyzed using SPSS for Windows VER 11.5 (SPSS Inc., Chicago, Ill, USA). Each variant was evaluated by one sample Kolmogorov-Smirnov test for compatibility with normal distribution. As the data did not fit normal distribution, the non-parametric Kruskall-Wallis test for intergroups comparison and Mann-Whitney U test or Bonferroni corrected Mann-Whitney U test or Bonferroni corrected were used for between-group comparisons as indicated. The relationship between variables was evaluated by Spearman correlation and regression analysis. Levels of significance set at 0.05 but in Bonferroni corrected test the significance threshold of 0.05 yielded to the value of 0.0167. Data are presented as median values and their individual ranges (in parenthesis).

3. RESULTS

Detected number of patients suffering from individual active clinical manifestations of the disease in various degrees was 31 with oral ulceration (44.28%), 23 with genital ulceration (32.85%), 18 with ocular involvement (25.71%), 37 with vascular involvement (52.85%), 25 with arthritis (35.71%), and 31 with cutaneous lesions like erythema nodosum (EN) and papulopustular eruption (PPE) (44.28%). Thirty five patients (50%) were found to have positive pathergy test. According to our evaluation scale, 34 patients were considered to have active disease with a median of 4 symptoms ranging between 2 and 5 and 36 patients to have inactive disease with a median of 1 symptom ranging between 1 and 2. Consistently, active group had a statistically significant high BDAI score with a median of 16 ranging between 1 and 25 compared to inactive group with a median of 2 ranging between 1 and 5 (P = .00) (Table 1). According to vascular examination, venous involvement (deep venous thrombosis with or without thromboelebitis) was found in 23 patients and either arterial occlusion or aneurysm was found in 14 patients in active group. 17 patients in inactive group had short duration of thromboelebitis with a wellbeing status.

In intergroup comparison of active BD, inactive BD, and healthy controls according to serum levels of Hcy, TNF-α, CRP, and ESR significant difference was detected for each parameter (P = .00 for each parameter) (Table 1). To determine which group/groups cause the difference, between-group comparisons performed. According to this, Hcy, TNF-α, CRP, and ESR levels were found elevated in active BD compared to inactive BD and healthy controls. Hcy, TNF-α, CRP, and ESR levels of inactive BD were found elevated compared to healthy controls. Hcy and TNF-α suggested having a strong association of disease activity (Table 1). Hcy and TNF-α were found to have high correlation with BDAI scores (r = 0.836, P = .00 and r = 0.924, P = .00, resp.) and the number of active clinical manifestations increased (r = 0.694, P = .00 and r = 0.842, P = .00, resp.) while ESR and CRP also showed a positive correlation with both parameters with relatively less significance (Table 2).

The evaluation of association between specific individual clinical manifestations and serum levels revealed increased Hcy levels in patients with oral ulcer (P = .03), genital ulcer (P = .005), the presence of positive pathergy test (P = .007), ocular lesion (P = .00), and vascular lesion of high significance (P = .00) (Table 3). No association was found between Hcy levels and EN/PPE and arthritis.

The serum levels of TNF-α were found to have strong association with oral ulcer (P = .00), genital ulcer (P = .00), the presence of positive pathergy test (P = .00), ocular lesion (P = .00), and vascular lesion (P = .00) (Table 4). No association was found between TNF-α levels and EN/PPE and arthritis.

The association of CRP with genital ulcer (P = .001), ocular lesion (P = .001), vascular lesion (P = .001), EN/PPE (P = .043), and the presence of positive pathergy test (P = .016) was found. No association was found between CRP levels and ocular lesion and arthritis (Table 5). ESR showed no significant association with any of the specific individual clinical manifestations (Table 6).

A significant positive correlation was found between serum Hcy and TNF-α levels (r = 0.89, P = .00), CRP (r = 0.645, P = .00) and ESR (r = 0.561, P = .00) (Table 2). Among parameters, Hcy was found to be the best predictor of TNF-α which was used as a dependent variable (Beta = 6.45, R² = 0.88, P = .00) (Table 7).

Serum levels of Hcy in active BD patients with vascular involvement were found significantly increased when compared in patients with active BD without vascular involvement. In addition, serum levels of Hcy in inactive BD with vascular involvement were found significantly increased compared to inactive BD (Table 8).

Serum levels of active BD patients with vascular involvement, oral ulcer, arthritis/arthritis, EN/PPE and the presence of positive pathergy test were found significantly increased compared to inactive BD patients with the same clinical symptoms (Table 9).

4. DISCUSSION

The main pathology in BD is an inflammatory process of small arteries and veins and thrombosis as a result of vasculitis of the vaso vasorum [24]. Hyperhomocysteinemia has been shown to be a risk factor for thrombosis in BD in some recent studies [14–19]. In our study, serum levels of Hcy were found to have a positive correlation with BDAI scores and total number of active clinical manifestations. We also found significantly elevated levels of serum total Hcy in active BD when compared with inactive and control groups. Our results supported that total serum Hcy was a reliable marker for the activity of disease [17]. Aksu et al. [14] divided their patients with BD into two groups on the basis of thrombosis and they found hyperhomocysteinemia in patients with a history of thrombosis. However, Leiba et al. [22] could not find different serum total Hcy levels between patients with and without a history of thrombosis. The main limitations of this study were its retrospective nature.
caused by vascular inflammation [14, 15]. The association of thrombosis in BD is thought to be endothelial dysfunction study.

10 patients were accepted as clinically active, though they their patients with respect to current clinical activity and the time of analyses performed. Aksu et al. [14] evaluated and the long lag period between the thrombotic events and the time of analyses performed. Aksu et al. [14] evaluated their patients with respect to current clinical activity and 10 patients were accepted as clinically active, though they could not find association between serum Hcy levels and disease activity. The small sample size was a limitation of this study.

Table 1: Comparision of serum homocysteine, TNF-α, CRP, and ESR values and BDAI scores between groups.

| Group           | Median (range) | Homocysteine ($\mu$mol/L) | TNF-α (pg/mL) | ESR (mm/h) | CRP (mg/L) | BDAI scores |
|-----------------|----------------|--------------------------|---------------|------------|------------|-------------|
| Group I (active BD) ($n = 34$) | 20.95 (13.7–39.25) | 93.5 (30–228) | 24 (2–95) | 20.5 (3–400) | 16 (9–25) |
| Group II (inactive BD) ($n = 36$) | 13 (6.43–18) | 19 (15–30) | 27 (8–49) | 6.65 (3–34) | 2 (1–5) |
| Group III (healthy control) ($n = 33$) | 8 (5–8) | 0 (0–18) | 6 (2–18) | 3.1 (3–10) |

Significance for groups

| Group   | I-II-III | I-II | I-III | II-III |
|---------|----------|------|-------|--------|
| Hcy     | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ |
| CRP     | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ |
| ESR     | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ |
| BDAI    | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ | $P = .00^*$ |

$^aP$ Significant different by Kruskal-Wallis test ($P < .05$).

$^bP$ Significant different by Bonferroni corrected Mann-Whitney U test ($P < .0167$).

$^cP$ Significant different by Mann-Whitney U test ($P < .05$).

Data are presented as median values and their individual ranges within parentheses.

Table 2: The relationship between variables.

|          | Hcy | ESR | CRP | TNF | Total† | BDAI |
|----------|-----|-----|-----|-----|--------|------|
| Spearman correlation coefficient and P-values |
| Hcy      | $r = 0.561$ | $P = .00$ | $r = 0.645$ | $P = .00$ | $r = 0.889$ | $P = .00$ | $r = 0.694$ | $P = .00$ | $r = 0.836$ |
| ESR      | $r = 0.561$ | $P = .00$ | $r = 0.421$ | $P = .00$ | $r = 0.538$ | $P = .00$ | $r = 0.304$ | $P = .00$ | $r = 0.408$ |
| CRP      | $r = 0.645$ | $P = .00$ | $r = 0.670$ | $P = .00$ | $r = 0.549$ | $P = .00$ | $r = 0.583$ |
| TNF      | $r = 0.889$ | $P = .00$ | $r = 0.670$ | $P = .00$ | $r = 0.842$ | $P = .00$ | $r = 0.924$ |
| Total†   | $r = 0.694$ | $P = .00$ | $r = 0.304$ | $P = .00$ | $r = 0.549$ | $P = .00$ | $r = 0.842$ |
| BDAI     | $r = 0.836$ | $P = .00$ | $r = 0.408$ | $P = .00$ | $r = 0.842$ | $P = .00$ | $r = 0.842$ |

$\dagger$ Number of active clinical manifestations for each patient.

and the long lag period between the thrombotic events and the time of analyses performed. Aksu et al. [14] evaluated their patients with respect to current clinical activity and 10 patients were accepted as clinically active, though they could not find association between serum Hcy levels and disease activity. The small sample size was a limitation of this study.

The main factor responsible for the increased frequency of thrombosis in BD is thought to be endothelial dysfunction caused by vascular inflammation [14, 15]. The association between Hcy levels and endothelial dysfunction and its correlation to the degree of endothelial damage has been shown in patients with BD [20]. Hcy generates superoxide and hydrogen peroxide, both of which have been linked to endothelial damage [15]. Hcy-induced vascular problems are thought to be multifactorial, including direct Hcy damage to the endothelium, enhanced lipid peroxidation and increased platelet aggregation by the effects on the coagulation system [15, 17].

In our study, the evaluation of association between specific individual clinical manifestations and serum levels revealed increased Hcy levels in patients with oral ulcer, genital ulcer, the presence of positive pathergy test and particularly with ocular and vascular lesions of high significance. No association was found between Hcy levels and EN/PPE and arthritis. Er et al. [15] showed the association of Hcy levels with disease activity and ocular BD. Other specific individual clinical manifestations were not assessed in this study. Ateş et al. [16] showed the association of Hcy levels with vascular involvement in BD. However, they could not find statistically significant difference between active and inactive diseases and association with mucocutaneous involvement in BD. On the other hand, Korkmaz et al. [28] reported no statistically significant association between vascular involvement and homocysteine levels, though 50% of patients with vascular involvement had hyperhomocysteinemia. Although the mechanism is unknown, all these findings indicate that Hcy associates with BD. However, the causes of these different study outcomes are not clear. The different sample sizes, different disease durations or study patients under treatment that might affect outcomes might have contributed. In addition, the question whether hyperhomocysteinemia depends on the inflammation or not remains to be unanswered.
Table 3: The significance of the association of Hcy with versus without individual clinical manifestations and pathergy reaction.

| Manifestations     | No. of Patients | Hcy levels (μmol/L) in patients with | Hcy levels (μmol/L) in patients without | P-values |
|--------------------|-----------------|--------------------------------------|----------------------------------------|----------|
| Oral ulcer         | 31              | 18.03 (8–39.3)                      | 14.28 (6.4–29)                         | P = .003*|
| Genital ulcer      | 23              | 18.1 (11.9–38.1)                    | 14.28 (6.4–39.3)                      | P = .005*|
| Ocular lesion      | 18              | 21.59 (14–39.3)                     | 14.15 (6.4–38)                        | P = .004*|
| Vascular lesion    | 37              | 19 (11.9–39.3)                      | 13.75 (6.4–26)                        | P = .004*|
| Arthritis/arthralgia | 25            | 16 (6.4–39.3)                      | 15 (8–38.1)                            | P = .99   |
| EN/PPE             | 31              | 16 (8.1–38.1)                      | 14.88 (6.4–39.3)                      | P = .306  |
| (+) pathergy       | 35              | 17.2 (7.9–38.1)                    | 14 (6.4–39.3)                         | P = .007*|

*P < .05 by Mann-Whitney U test (statistically significant with versus without clinical manifestations).

Data are presented as median values and their individual ranges within parentheses.

Table 4: The significance of the association of TNF-α with versus without individual clinical manifestations and pathergy reaction.

| Manifestations     | No. of patients | TNF-α levels (pg/mL) in patients with | TNF-α levels (pg/mL) in patients without | P-values |
|--------------------|-----------------|--------------------------------------|----------------------------------------|----------|
| Oral ulcer         | 31              | 70 (15–228)                          | 20 (15–150)                            | P = .008*|
| Genital ulcer      | 23              | 54 (17–228)                          | 21 (15–228)                            | P = .009*|
| Ocular lesion      | 18              | 99 (30–228)                          | 21 (15–180)                            | P = .009*|
| Vascular lesion    | 37              | 84 (15–228)                          | 21 (15–145)                            | P = .012*|
| Arthritis/arthralgia | 25            | 38 (15–228)                          | 28 (15–228)                            | P = .49   |
| EN/PPE             | 31              | 45 (15–228)                          | 22 (15–228)                            | P = .086  |
| (+) pathergy       | 35              | 45 (15–228)                          | 21 (15–228)                            | P = .009*|

*P < .05 by Mann-Whitney U test (statistically significant with versus without clinical manifestations).

Data are presented as median values and their individual ranges within parentheses.

Table 5: The significance of the association of CRP with versus without individual clinical manifestations and pathergy reaction.

| Manifestations     | No. of patients | CRP levels (mg/L) in patients with | CRP levels (mg/L) in patients without | P-values |
|--------------------|-----------------|------------------------------------|--------------------------------------|----------|
| Oral ulcer         | 31              | 12.4 (3–400)                       | 8.7 (3–43)                           | P = .159 |
| Genital ulcer      | 23              | 18 (3–100)                         | 8.4 (3–400)                          | P = .001*|
| Ocular lesion      | 18              | 19.25 (3–400)                     | 8.5 (3–68)                           | P = .001*|
| Vascular lesion    | 37              | 20.5 (3–400)                       | 8.4 (3–51)                           | P = .001*|
| Arthritis/arthralgia | 25            | 8.4 (3–400)                       | 12.9 (3–400)                        | P = .201 |
| EN/PPE             | 31              | 12.9 (3–400)                      | 8.9 (3–400)                          | P = .043*|
| (+) pathergy       | 35              | 14.8 (3–400)                       | 8.7 (3–400)                          | P = .016*|

*P < .05 by Mann-Whitney U test (statistically significant with versus without clinical manifestations).

Data are presented as median values and their individual ranges within parentheses.

Table 6: The significance of the association of ESR with versus without individual clinical manifestations and pathergy reaction.

| Manifestations     | No. of patients | ESR levels (mm/h) in patients with | ESR levels (mm/h) in patients without | P-values |
|--------------------|-----------------|-----------------------------------|--------------------------------------|----------|
| Oral ulcer         | 31              | 12 (2–95)                          | 12 (2–70)                            | P = .113 |
| Genital ulcer      | 23              | 22 (2–95)                          | 14 (2–60)                            | P = .121 |
| Ocular lesion      | 18              | 22 (2–86)                          | 14 (2–95)                            | P = .291 |
| Vascular lesion    | 37              | 20 (2–70)                          | 14 (2–95)                            | P = .642 |
| Arthritis/arthralgia | 25            | 22 (3–60)                          | 14 (2–95)                            | P = .317 |
| EN/PPE             | 31              | 24 (2–95)                          | 12 (2–70)                            | P = .070 |
| (+) pathergy       | 35              | 22 (2–95)                          | 14 (3–49)                            | P = .173 |

*P < .05 by Mann-Whitney U test (statistically significant with versus without clinical manifestations).

Data are presented as median values and their individual ranges within parentheses.
That is because most clinical features are thought for vascular and ocular vaso-occlusive diseases in BD cannot simply be assumed to be an independent risk factor for any organ system may be affected, there is high prevalence of venous or arterial thrombosis in BD and most clinical features are associated with systemic vasculitis. It has been suggested that vasculo-Behcet disease should be classified as a neutrophilic vasculitis targeting the vaso vasorum [32]. Aneurysm formation may be related to degeneration of arterial wall caused by inflammation of the vaso vasorum. As Hcy has profound effects concerning vascular lesions and thrombosis, vascular and ocular involvements in BD deserve special attention. Indeed, we found significantly elevated levels of Hcy with respect to the presence of vascular involvement in the intragroup comparisons of separately active and inactive BD patients. However, in our study Hcy was found to be able to evaluate the fluctuating activity of disease in an objective fashion and the number of additional organ systems affected. This finding may imply that Hcy cannot simply be assumed to be an independent risk factor for only vascular and ocular vaso-occlusive diseases in BD [15–19]. That is because most clinical features are thought to be associated with systemic vasculitis and dermal blood vessels embolized by thrombus are observed even at the sites of needle-prick reaction [30]. Furthermore, endothelial injury is a characteristic finding in BD and can be observed even in patients without any clinical vascular involvement [24, 33, 34]. These data provides insight as to why Hcy is able to detect overall disease activity with respect to different system involvements and why ascribed significance of Hcy is not limited only to the individual clinical manifestations of vascular or vaso-occlusive ocular involvements? Consistently, we found the association of Hcy not only with vascular and ocular vaso-occlusive disease but also with genital ulceration, positive pathergy test, and oral ulcers in BD patients, though with less significance. Therefore, our results not only support the suggestion that Hcy is a risk factor for vascular and ocular vaso-occlusive diseases in BD [15, 16] but also identify Hcy as a risk factor for the development of most clinical features that are known to be associated with vasculitis.

We found a significant positive correlation between serum Hcy, TNF-α and CRP levels, and ESR with relatively less significance. Hcy was found to be the best predictor of TNF-α among other parameters. In other words, Hcy was found to explain 88% of TNF-α change while CRP and ESR were found to explain 39% and 14% of TNF-α change, respectively. The significance of Hcy in BD represents either vascular endothelium damaged by Hcy or immune system stimulation by Hcy, our study may demonstrate the link between Hcy and inflammation pathways in BD. That is because TNF-α, CRP, and ESR are indices of inflammation. Although there are conflicting results in the literature with respect to the reliability of ESR and CRP as markers to detect the activity of BD and they are currently not involved as criteria in BDAI scores [27], CRP deserves special attention because it has a strong predictive power of vascular events [35]. We found both of them were elevated in the active stage of the disease. However, unlike CRP, ESR showed no significant association with any of the specific individual clinical manifestations. Relatively large sample size of our patients with vascular involvement might be a factor affecting our study outcome in favor of the significance of CRP in BD.

Chemotactic and phagocytic activities of neutrophils in patients with BD have been reported to be high [31] and TNF-α is a major factor modulating inflammatory responses which is known to be increased in inflammatory diseases. Recent studies showed increased TNF-α level in BD patients, especially in the exacerbation period [24, 30]. Synthesis of CRP in the liver is induced by several proinflammatory cytokines including TNF-α. This marks CRP as a precise objective index of inflammatory activity and surrogate of underlying cytokine stimulus and a sensitive marker of underlying systemic inflammation [35]. It has been demonstrated that coagulation indices including fibrinogen, von Willebrand factor, and plasminogen activator protein-1 (MPC-1) [39]. Hcy was shown to enhance the cytokine-stimulated expression of endothelial cell adhesion molecules and monocyte and T-cell adhesion to endothelial cells [39]. Adhesion molecules are characterized not only by their ability to cause directed migration of leukocytes into inflamed tissue, but they may also have biological effects on

**Table 7: Predictors of plasma TNF-α level: regression analysis.**

| Predictor of TNF-α | R² | Beta | P-value |
|--------------------|----|------|---------|
| Hcy                | 0.88 | 6.45 | 0.00    |
| CRP                | 0.39 | 0.559| 0.00    |
| ESR                | 0.146| 1.15 | 0.00    |

Dependent variable: TNF-α.
other cell types, such as endothelial cells, fibroblasts, and smooth muscle cells [40]. Hcy was shown to promote TNF-α mediated induction of vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells [41]. With respect to innate inflammatory markers such as TNF-α and CRP, serum Hcy has been shown to contribute to innate immune response and to be a determinant of TNF-α in hypertensive patients [36]. In addition, Hcy has been shown to enhance inflammation markers in murine models [42]. The correlation of Hcy levels with nitric oxide has been shown in patients with BD [15]. Hcy is known to increase nitric oxide production in vascular smooth muscle cells and nitric oxide is known to be released as a response to systemic immunoinflammatory diseases [15]. A study demonstrated that targeting the TNF pathway significantly decreased Hcy and CRP levels in patients with psoriatic arthritis and in this study, CRP showed a positive correlation with Hcy at baseline [43]. CRP has been shown to correlate with Hcy in BD [19]. Hcy has been suggested to be related to the markers of inflammation and its elevated levels as a result of immunosuppressive treatment [19]. Indeed, immunosuppressive treatments may affect serum levels of Hcy and TNF-α [44]. This is the reason why we studied with the patients who were not taking any medication regarding BD. This definite selection decreased the number of our study population as a study limitation. In our study, serum levels of active BD patients with vascular involvement, oral ulcer, arthritis/arthralgia, EN/PPE and the presence of positive pathergy test were found significantly increased compared to inactive BD patients with the same clinical symptoms. Therefore, serum levels of Hcy were found to explain the wide clinical spectrum of the activity of the specific individual symptoms.

In summary, Hcy and CRP have effects into the mechanism linking inflammation and coagulation and Hcy is thought to induce proinflammatory cytokines including TNF-α, which is known to increase chemotactic and phagocytic activities of neutrophils, endothelial-leukocyte interaction, and CRP levels. We found a high correlation between serum levels of Hcy and TNF-α and Hcy was found to explain the wide clinical spectrum of the activity of the disease and specific individual symptoms. Taking all these findings into account, a theory might be put forward which is open to further in vivo and in vitro studies; Hcy-induced inflammation may be responsible for tissue damage as well as endothelial dysfunction in BD and enhanced Hcy may account for the differences observed between clinically distinct subgroups. Lowering Hcy by selected vitamin supplements or TNF blockade may be the future direction of prevention from developing the risk of thrombosis and vasculitis of different organ systems and thereby activation of BD disease.

5. CONCLUSION

Our data identified Hcy as a risk factor for the development of not only vascular and ocular involvement but also most clinical features that are known to be associated with vasculitis in BD. In addition, serum Hcy showed a strong association of disease activity and correlated with BDAI scores and the number of active clinical manifestations increased. Therefore, Hcy might be assumed as a reliable marker for the activity of disease. Hcy was found to be the best predictor of TNF-α and positively correlated with inflammatory markers. Our findings suggest that Hcy might contribute to the pathogenesis of BD by inducing inflammation. Further investigation in clinical and experimental studies is required to conclusively demonstrate the association between Hcy and inflammatory pathways.
ACKNOWLEDGMENT

The authors wish to thank Banu Tabanli, Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey, for statistical editing.

REFERENCES

[1] K. S. McCully, “Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis,” American Journal of Pathology, vol. 56, no. 1, pp. 111–128, 1969.

[2] L. A. Harker, S. J. Slichter, C. R. Scott, and R. Ross, “Homocystinemia. Vascular injury and arterial thrombosis,” The New England Journal of Medicine, vol. 291, no. 11, pp. 537–543, 1974.

[3] L. A. Harker, J. M. Harlan, and R. Ross, “Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons,” Circulation Research, vol. 53, no. 6, pp. 731–739, 1983.

[4] M. Hanzrani, J. I. Gillespie, and G. Stansby, “Homocysteine in myointimal hyperplasia,” European Journal of Vascular and Endovascular Surgery, vol. 23, no. 1, pp. 3–10, 2002.

[5] M. Den Heijer, F. R. Rosendaal, H. J. Bloem, W. B. J. Gerrits, and G. M. J. Bos, “Hyperhomocysteinemia and venous thrombosis: a meta-analysis,” Thrombosis and Haemostasis, vol. 80, no. 6, pp. 874–877, 1998.

[6] J. G. Ray, “Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease,” Archives of Internal Medicine, vol. 158, no. 19, pp. 2101–2106, 1998.

[7] D. S. Wald, M. Law, and J. K. Morris, “Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis,” British Medical Journal, vol. 325, no. 7374, pp. 1202–1206, 2002.

[8] R. Clarke, R. Collins, S. Lewington, et al., “Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis,” The Journal of the American Medical Association, vol. 288, no. 16, pp. 2015–2022, 2002.

[9] P. Durand, M. Prost, N. Loreau, S. Lussier-Cacan, and D. Blache, “Impaired homocysteine metabolism and atherothrombotic disease,” Laboratory Investigation, vol. 81, no. 5, pp. 645–672, 2001.

[10] G. J. Hankey and J. W. Elkelboom, “Homocysteine and vascular disease,” The Lancet, vol. 354, no. 9176, pp. 407–413, 1999.

[11] H. Behcet, “Über rezidivierende, aphthöse, durch ein virus verursachte Geschwüre am Mund am Auge und an den Genitalien,” Dermatol Wochenschr, vol. 105, pp. 1152–1157, 1937.

[12] Y. Koc, I. Gülü, G. Akpek, et al., “Vascular involvement in Behçet's disease,” Journal of Rheumatology, vol. 19, no. 3, pp. 402–410, 1992.

[13] N. P. B. Dudman, S. E. Temple, X. W. Guo, W. Fu, and M. A. Perry, “Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo,” Circulation Research, vol. 84, no. 4, pp. 409–416, 1999.

[14] K. Aksu, N. Turgan, E. Oksel, et al., “Hyperhomocysteinaemia in Behcet’s disease,” Rheumatology, vol. 40, no. 6, pp. 687–690, 2001.

[15] H. Er, C. Evereklioglu, T. Cumurcu, et al., “Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behcet’s disease,” British Journal of Ophthalmology, vol. 86, no. 6, pp. 653–657, 2002.

[16] A. Ateş, O. Aydın, U. Öljmez, N. Düzgün, and M. Duman, “Serum homocysteine level is higher in Behçet’s disease with vascular involvement,” Rheumatology International, vol. 25, no. 1, pp. 42–44, 2005.

[17] T. Sarican, H. Ayabakan, S. Turkmen, V. Kalasioglu, F. Baran, and N. Yenice, “Homocysteine: an activity marker in Behçet’s disease?” Journal of Dermatological Science, vol. 45, no. 2, pp. 121–126, 2007.

[18] Y. Özkan, S. Yardim-Akaydin, A. Sepic, B. Engin, V. Sepic, and B. Şimşek, “Assessment of homocysteine, neopterin and nitric oxide levels in Behçet’s disease,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 1, pp. 73–77, 2007.

[19] Z. Yesilova, S. Pay, C. Oktentli, et al., “Hyperhomocysteinemia in patients with Behcet’s disease: is it due to inflammation or therapy?” Rheumatology International, vol. 25, no. 6, pp. 423–428, 2005.

[20] R. Ozdemir, I. Barutcu, A. T. Sezgin, et al., “Vascular endothelial function and plasma homocysteine levels in Behçet's disease,” The American Journal of Cardiology, vol. 94, no. 4, pp. 522–525, 2004.

[21] Y. J. Lee, S. W. Kang, J. I. Yang, et al., “Coagulation parameters and plasma total homocysteine levels in Behçet’s disease,” Thrombosis Research, vol. 106, no. 1, pp. 19–24, 2002.

[22] M. Leiba, U. Seligsohn, Y. Sidi, et al., “Thrombophilic factors are not the leading cause of thrombosis in Behçet’s disease,” Annals of the Rheumatic Diseases, vol. 63, no. 11, pp. 1445–1449, 2004.

[23] J. Selhub, P. F. Jacques, P. W. Wilson, D. Rush, and I. H. Rosenberg, "Vitamin status and intake as primary determinants of homocysteinemia in an elderly population," The Journal of the American Medical Association, vol. 270, no. 22, pp. 2693–2698, 1993.

[24] C. Evereklioglu, H. Er, Y. Türköz, and M. Çekmen, "Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease," Mediators of Inflammation, vol. 11, no. 2, pp. 87–93, 2002.

[25] B. Wechsler, F. Dovatchi, Y. Mizushima, et al., "Criteria for diagnosis of Behçet’s disease," The Lancet, vol. 335, no. 8697, pp. 1078–1080, 1990.

[26] B. B. Bhakta, P. Brennan, T. E. James, M. A. Chamberlain, B. A. Noble, and A. J. Silman, "Behçet’s disease: evaluation of a new instrument to measure clinical activity," Rheumatology, vol. 38, no. 8, pp. 728–733, 1999.

[27] G. Lawton, B. B. Bhakta, M. A. Chamberlain, and A. Tennant, "The Behçet’s disease activity index," Rheumatology, vol. 43, no. 1, pp. 73–78, 2004.

[28] C. Korkmaz, B. Bozan, M. Kosar, F. Sahin, and Z. Gülbas, "Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet’s syndrome?" Clinical and Experimental Rheumatology, vol. 20, no. 4, supplement 26, pp. S30–S34, 2002.

[29] J.-L. Mege, P. Decorte, V. Cassuto, et al., "Over production of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects," Journal of Rheumatology, vol. 20, no. 9, pp. 1544–1549, 1993.

[30] C. Evereklioglu, "Current concepts in the etiology and treatment of Behçet disease," Survey of Ophthalmology, vol. 50, no. 4, pp. 297–350, 2005.

[31] M. Baggio, B. Dewald, and B. Moser, "Human chemokines: an update," Annual Review of Immunology, vol. 15, pp. 675–705, 1997.
[32] M. Kobayashi, M. Ito, A. Nakagawa, et al., “Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease,” Histopathology, vol. 36, no. 4, pp. 362–371, 2000.

[33] I. C. Haznedaroglu, O. Ozdemir, O. Ozcebe, S. V. Dundar, and S. Kirazli, “Circulating thrombomodulin as a clue of endothelial damage in Behçet’s disease,” Thrombosis and Haemostasis, vol. 75, no. 6, pp. 974–975, 1996.

[34] I. C. Haznedaroglu, O. I. Ozcebe, O. Ozdemir, I. Çelik, S. V. Dündar, and Ş. Kirazli, “Impaired haemostatic kinetics and endothelial function in Behçet’s disease,” Journal of Internal Medicine, vol. 240, no. 4, pp. 181–187, 1996.

[35] T. Ohkuma, T. Minagawa, N. Takada, M. Ohno, H. Oda, and H. Ohashi, “C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients,” American Journal of Kidney Diseases, vol. 42, no. 2, pp. 355–361, 2003.

[36] P. Bogdanski, D. Pupek-Musialik, J. Dytfeld, M. Lacinski, A. Jablecka, and H. Jakubowski, “Plasma homocysteine is a determinant of tissue necrosis factor-α in hypertensive patients,” Biomedicine and Pharmacotherapy, vol. 62, no. 6, pp. 360–365, 2008.

[37] A. M. Gori, A. M. Corsi, S. Fedi, et al., “A proinflammatory state is associated with hyperhomocysteinemia in the elderly,” American Journal of Clinical Nutrition, vol. 82, no. 2, pp. 335–341, 2005.

[38] B. Widner, F. Leblhuber, B. Frick, A. Laich, E. Artner-Dworzak, and D. Fuchs, “Moderate hyperhomocysteinaemia and immune activation in Parkinson’s disease,” Journal of Neural Transmission, vol. 109, no. 12, pp. 1445–1452, 2002.

[39] T. Koga, K. Claycombe, and M. Meydani, “Homocysteine increases monocyte and T-cell adhesion to human aortic endothelial cells,” Atherosclerosis, vol. 161, no. 2, pp. 365–374, 2002.

[40] M. Li, J. Chen, Y.-S. Li, Y.-B. Feng, X. Gu, and C.-Z. Shi, “Folic acid reduces adhesion molecules VCAM-1 expression in aortic of rats with hyperhomocysteinemia,” International Journal of Cardiology, vol. 106, no. 2, pp. 285–288, 2006.

[41] M. D. Silverman, R. J. Tumuluri, M. Davis, G. Lopez, J. T. Rosenbaum, and P. I. Lelkes, “Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion,” Atherosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 4, pp. 587–592, 2002.

[42] M. A. Hofmann, E. Lalla, Y. Lu, et al., “Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model,” The Journal of Clinical Investigation, vol. 107, no. 6, pp. 675–683, 2001.

[43] N. Sattar, P. Crompton, L. Cherry, D. Kane, G. Lowe, and I. B. McInnes, “Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study,” Arthritis & Rheumatism, vol. 56, no. 3, pp. 831–839, 2007.

[44] M. Ballow and R. Nelson, “Immunopharmacology: immunomodulation and immunotherapy,” The Journal of the American Medical Association, vol. 278, no. 22, pp. 2008–2017, 1997.